E. Ohman J or Asset Management AB Boosts Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

E. Ohman J or Asset Management AB lifted its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 23.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 42,981 shares of the company's stock after buying an additional 8,200 shares during the quarter. E. Ohman J or Asset Management AB owned approximately 0.11% of Tarsus Pharmaceuticals worth $2,208,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Rhumbline Advisers raised its holdings in shares of Tarsus Pharmaceuticals by 4.3% in the 1st quarter. Rhumbline Advisers now owns 51,682 shares of the company's stock valued at $2,655,000 after buying an additional 2,148 shares during the period. GAMMA Investing LLC increased its holdings in Tarsus Pharmaceuticals by 36,430.6% during the 1st quarter. GAMMA Investing LLC now owns 13,151 shares of the company's stock worth $676,000 after purchasing an additional 13,115 shares during the period. Toronto Dominion Bank purchased a new stake in Tarsus Pharmaceuticals during the 4th quarter worth about $105,714,000. GF Fund Management CO. LTD. purchased a new stake in Tarsus Pharmaceuticals during the 4th quarter worth about $44,000. Finally, Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. purchased a new stake in Tarsus Pharmaceuticals during the 4th quarter worth about $3,278,000. Hedge funds and other institutional investors own 90.01% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. The Goldman Sachs Group upped their price target on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a "neutral" rating in a report on Monday, May 5th. Barclays cut their price target on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Jefferies Financial Group upped their price target on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a "buy" rating in a report on Thursday, March 6th. Guggenheim upped their price target on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Finally, Wall Street Zen downgraded Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 22nd. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $66.67.

Tarsus Pharmaceuticals Trading Down 0.4%

NASDAQ:TARS opened at $43.92 on Friday. The stock has a 50-day simple moving average of $46.22 and a 200-day simple moving average of $48.85. The stock has a market cap of $1.85 billion, a P/E ratio of -11.53 and a beta of 0.83. Tarsus Pharmaceuticals, Inc. has a 1 year low of $20.08 and a 1 year high of $57.28. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.05. The business had revenue of $78.34 million during the quarter, compared to analysts' expectations of $72.50 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. As a group, analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Insider Activity at Tarsus Pharmaceuticals

In related news, insider Dianne C. Whitfield sold 2,137 shares of the company's stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $50.11, for a total value of $107,085.07. Following the completion of the sale, the insider now directly owns 46,355 shares of the company's stock, valued at $2,322,849.05. This represents a 4.41% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Bryan Wahl sold 3,341 shares of the company's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $154,654.89. Following the completion of the sale, the general counsel now directly owns 58,057 shares of the company's stock, valued at approximately $2,687,458.53. This trade represents a 5.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 32,542 shares of company stock valued at $1,581,173 in the last three months. 8.97% of the stock is currently owned by company insiders.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.